These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11861264)

  • 1. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.
    Baccarani M; Rosti G; de Vivo A; Bonifazi F; Russo D; Martinelli G; Testoni N; Amabile M; Fiacchini M; Montefusco E; Saglio G; Tura S;
    Blood; 2002 Mar; 99(5):1527-35. PubMed ID: 11861264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
    Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia.
    Rosti G; Bonifazi F; Trabacchi E; De Vivo A; Bassi S; Martinelli G; Testoni N; Russo D; Baccarani M
    Leukemia; 2003 Mar; 17(3):554-9. PubMed ID: 12646944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.
    Lindauer M; Fischer T
    Leuk Lymphoma; 2001 May; 41(5-6):523-33. PubMed ID: 11378570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Deininger MW
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.